← Back to Clinical Trials
Recruiting NCT06297252

NCT06297252 Prevalence of Psychiatric Disorders During Pregnancy at 2nd Trimester Ultrasound: a Feasibility Study in the General Population

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06297252
Status Recruiting
Phase
Sponsor University Hospital, Montpellier
Condition Pregnancy
Study Type INTERVENTIONAL
Enrollment 140 participants
Start Date 2024-04-25
Primary Completion 2026-04-24

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
standardized clinical psychiatric evaluationsself-administered psychiatric questionnaire assessmentsblood sampling

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 140 participants in total. It began in 2024-04-25 with a primary completion date of 2026-04-24.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Young women represent a population at risk of psychiatric disorders, the first signs of which often appear between the ages of 15 and 25. Psychiatric disorders are a major source of disability and healthcare costs. The perinatal period is an additional period of psychological vulnerability, during which women are at increased risk of developing or worsening psychiatric disorders. Unfortunately, psychiatric disorders seem to be largely under-diagnosed during this period, and therefore under-treated. The goal of this Prospective multicenter study is to determine the prevalence of the presence of at least one characterized psychiatric disorder, as defined by the use of the Mini International Neuropsychiatric Interview (MINI), in remission or not, during pregnancy, at the time of the second-trimester ultrasound (T2 ultrasound) based on a standardized clinical assessment. Participants will complete self-questionnaires and have a standardized psychiatric evaluation at T2 ultrasound and at 2 months postpartum.

Eligibility Criteria

Inclusion Criteria: * Women * 18 years and over * Pregnant and consulting for scheduled second trimester ultrasound * Able to read and write with a good knowledge of French Exclusion Criteria: * Unable to understand French * Illiterate * Underage patient at time of second trimester ultrasound * Patient under guardianship or curatorship * Patient deprived of liberty * Patient not affiliated to or not benefiting from a social security scheme * Refusal of consent after information * Participant in another research project with an ongoing exclusion period

Contact & Investigator

Central Contact

Raoul Belzeaux, MD PhD

✉ raoul.belzeaux@chu-montpellier.fr

📞 04 67 33 79 13

Principal Investigator

Raoul Belzeaux, MD PhD

STUDY DIRECTOR

University Hospital, Montpellier

Frequently Asked Questions

Who can join the NCT06297252 clinical trial?

This trial is open to female participants only, aged 18 Years or older, studying Pregnancy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06297252 currently recruiting?

Yes, NCT06297252 is actively recruiting participants. Contact the research team at raoul.belzeaux@chu-montpellier.fr for enrollment information.

Where is the NCT06297252 trial being conducted?

This trial is being conducted at Béziers, France, Montpellier, France.

Who is sponsoring the NCT06297252 clinical trial?

NCT06297252 is sponsored by University Hospital, Montpellier. The principal investigator is Raoul Belzeaux, MD PhD at University Hospital, Montpellier. The trial plans to enroll 140 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology